Beyond that, TAAs such as fibroblast activation protein (FAP), and EGFR could also be partnered with CD137 agonists on a single MSN platform to ensure tumor-specific T cell activation, as supported by earlier studies 49, 61. Here, TNFRSF9 is linked to neoplasm.